BRPI0916241A2 - formulações farmacêuticas contendo ligantes de receptores de dopamina - Google Patents

formulações farmacêuticas contendo ligantes de receptores de dopamina

Info

Publication number
BRPI0916241A2
BRPI0916241A2 BRPI0916241A BRPI0916241A BRPI0916241A2 BR PI0916241 A2 BRPI0916241 A2 BR PI0916241A2 BR PI0916241 A BRPI0916241 A BR PI0916241A BR PI0916241 A BRPI0916241 A BR PI0916241A BR PI0916241 A2 BRPI0916241 A2 BR PI0916241A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
formulations containing
dopamine receptor
containing dopamine
receptor binders
Prior art date
Application number
BRPI0916241A
Other languages
English (en)
Inventor
Chettry Anil
G Dedhiya Mahendra
Sarkar Ranajoy
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916241(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of BRPI0916241A2 publication Critical patent/BRPI0916241A2/pt
Publication of BRPI0916241B1 publication Critical patent/BRPI0916241B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04NPICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N25/00Circuitry of solid-state image sensors [SSIS]; Control thereof
    • H04N25/70SSIS architectures; Circuits associated therewith
    • H04N25/76Addressed sensors, e.g. MOS or CMOS sensors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0916241-0A 2008-07-16 2009-07-16 Formulação farmaucêutica contendo ligantes de receptores de dopamina e seu uso BRPI0916241B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8105208P 2008-07-16 2008-07-16
US61/081,052 2008-07-16
PCT/US2009/050835 WO2010009309A1 (en) 2008-07-16 2009-07-16 Pharmaceutical formulations containing dopamine receptor ligands

Publications (2)

Publication Number Publication Date
BRPI0916241A2 true BRPI0916241A2 (pt) 2017-06-27
BRPI0916241B1 BRPI0916241B1 (pt) 2025-09-30

Family

ID=

Also Published As

Publication number Publication date
NZ590852A (en) 2013-03-28
DK2317852T3 (en) 2015-03-23
USRE47350E1 (en) 2019-04-16
UA104869C2 (uk) 2014-03-25
AP2975A (en) 2014-09-30
USRE49302E1 (en) 2022-11-15
NI201100016A (es) 2011-08-03
KR101612146B1 (ko) 2016-04-12
JP2011528374A (ja) 2011-11-17
MA32568B1 (fr) 2011-08-01
USRE47333E1 (en) 2019-04-02
CN104997743A (zh) 2015-10-28
EA025636B1 (ru) 2017-01-30
CA2730287C (en) 2017-02-07
GEP20146052B (en) 2014-03-10
WO2010009309A1 (en) 2010-01-21
IL210615A0 (en) 2011-03-31
EP2317852A1 (en) 2011-05-11
CL2011000091A1 (es) 2011-07-22
ES2532636T3 (es) 2015-03-30
US20130040966A1 (en) 2013-02-14
CN102118970A (zh) 2011-07-06
CY1115994T1 (el) 2017-01-25
IL210615A (en) 2015-03-31
USRE49110E1 (en) 2022-06-21
EP2317852B1 (en) 2014-12-24
MX2011000622A (es) 2011-04-07
AP2011005549A0 (en) 2011-02-28
SMT201500063B (it) 2015-05-05
KR20110033852A (ko) 2011-03-31
EA201170198A1 (ru) 2011-08-30
PT2317852E (pt) 2015-03-24
US9056846B2 (en) 2015-06-16
RS53866B1 (sr) 2015-08-31
AU2009270823A1 (en) 2010-01-21
US20100016334A1 (en) 2010-01-21
ECSP11010834A (es) 2011-04-29
AU2009270823B2 (en) 2014-07-17
CO6351689A2 (es) 2011-12-20
US9056845B2 (en) 2015-06-16
PL2317852T3 (pl) 2015-05-29
EP2317852A4 (en) 2011-10-05
JP5774988B2 (ja) 2015-09-09
ZA201101134B (en) 2011-10-26
CA2730287A1 (en) 2010-01-21
MY156288A (en) 2016-01-29
HRP20150196T1 (hr) 2015-06-05
SI2317852T1 (sl) 2015-04-30
SG192507A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
PT2317852E (pt) Formulações farmacêuticas contendo ligandos de recetor de dopamina
LTPA2018005I1 (lt) Farmacinė kompozicija
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0721651A2 (pt) Composição farmacêutica
BR112012011733A2 (pt) formulações de comprimido de liberação imediata
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
BRPI0908114A2 (pt) tabuleta oral de liberação controlada
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0918064A2 (pt) distribuidor de substância
DK2120884T3 (da) Farmaceutisk sammensætning
DK2285413T3 (da) Farmaceutisk sammensætning
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0912171A2 (pt) composição farmacêutica
BRPI0806938A2 (pt) Composição farmacêutica contedo um derivado de camptotecina
BRPI0921301A2 (pt) composição farmacêutica
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
BRPI0913058A2 (pt) composições farmacêuticas de conjugados somatostatina/dopamina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.